Ann: PTX100 Ph1b results to be presented at specialist congress, page-9

Hi,

I highly doubt that the FDA would include the current patients in the next phase numbers.

Hopefully the FDA agree on a registrational trial, hopefully they agree to a compact trial given the unmet need of the targeted disease.

The FDA would want to satisfy the question of efficacy without hamstringing us by creating a massive framework that is both costly and hard to recruit for.

Hopefully Steven and the FDA can arrive on a palatable framework, that cuts through the red tape and gets this drug into the hands of clinicians.

See what happens but I'm still quietly confident of a registrational trial.

Good luck to all,